CD28 and lymphoma: Compared to conventional T-CAR that is driven by CD28 and CD3ζ signaling domains, this NK-tailored CAR produced a more potent antitumor cytotoxic activity in NK cells, both in vitro and in vivo, in a model of CD19-expressing lymphoma.